Evidence map›Paper›PMID 40124619›Full record

ArticlePeerJ2025

A combination of hepatic leukemia factor and circulating tumor cells serve as effective biomarkers for lung adenocarcinoma prognosis.

Yaofeng Zhi, Jinhua Wu, Ronggang Li, Xuefei Chang, Silin Liu, Wenjie Lu, Mingzhu Zheng, Baoyi Liu, Jiarong Chen, Xin Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yaofeng Zhi *Clinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Jinhua Wu *Department of Clinical Laboratory, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Ronggang LiDepartment of Pathology, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Xuefei ChangClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Silin LiuClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Wenjie LuClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Mingzhu ZhengClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Baoyi LiuClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Jiarong ChenClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Xin ZhangClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Yanming HuangClinical Experimental Center, Jiangmen Engineering Technology Research Center of Clinical Biobank and Translational Research, Jiangmen Key Laboratory of Precision and Clinical Translation Medicine, Jiangmen Central Hospital, Jiangmen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) is a highly malignant tumor with the highest mortality rate among all cancers. Early diagnosis and prognosis are important factors in treatment. Hepatic leukemia factor (HLF) is thought to be closely associated with lung cancer metastasis. It is downregulated in lung cancer tissues and negatively correlated with the number of metastasis-activating circulating tumor cells (CTCs) in the peripheral blood of patients. Method and Results: In this study, we analyzed data from LUAD samples in TCGA and found that HLF was significantly upregulated in samples with EGFR mutations. Immunohistochemical (IHC) staining of 343 clinical samples also revealed a trend of HLF upregulation in patients with EGFR mutations. EGFR is one of the driver genes in non-small cell lung cancer (NSCLC), and the proportion in LUAD is as high as 50% in the East Asian population. In this study, EGFR mutation was not significantly correlated with the prognosis of LUAD patients and the number of CTC was also not related to EGFR mutation, but was closely related to HLF expression, with more CTCs being captured in the peripheral blood of patients with low expression of HLF (SI ≤ 4). By following up these 343 LUAD patients, high HLF expression (SI > 4) was found to be an independent protective factor for progression-free survival regardless of EGFR status ( Conclusion: In summary, we believe that HLF expression in cancer tissues and the number of CTCs can be used as effective biomarkers for predicting the prognosis of LUAD, which plays an important role in clinical diagnosis and prognosis judgment.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsNeoplastic Cells, CirculatingAgedErbB ReceptorsFemaleHumansMaleMiddle AgedMutationPrognosisBiomarkers, TumorEGFR protein, humanErbB ReceptorsBiomarkerCirculating tumor cellsHepatic leukemia factorLung adenocarcinomaPrognosis

Identifiers

PMID40124619
PMCPMC11927566

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.